Skip to main content
Premium Trial:

Request an Annual Quote

Palisade Bio, Strand Life Sciences Partner for Ulcerative Colitis Precision Medicine

NEW YORK – Palisade Bio announced on Tuesday that it entered into a strategic collaboration with Strand Life Sciences to advance precision medicine for ulcerative colitis, including its lead PDE4 inhibitor, PALI-2108.

The agreement provides Palisade Bio with access to Strand's bioinformatics tools for analyzing complex disease pathways and predicting patient response to PDE4 inhibitors.

Financial details of the agreement were not provided.

Carlsbad, California-based Palisade has curated a 1,600-patient dataset that includes transcriptomics and clinical outcomes, using data from more than 10 ulcerative colitis studies. Via machine learning, Palisade uses this dataset to identify biomarkers for selecting patients responsive to therapy.

"By harnessing the power of bioinformatics and leveraging extensive patient datasets, we are highly optimistic in our ability to deliver personalized therapies that offer new hope to patients living with [ulcerative colitis]," Mitch Jones, chief medical officer of Palisade Bio, said in a statement. "More immediately, the findings from this collaboration will provide valuable guidance and insight for our lead program, PALI-2108."